SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
Annual Report pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
For the fiscal year ended June 27, 1998 Commission file number 0-14742
CANDELA CORPORATION
-------------------
(Exact name of registrant as specified in its charter)
Delaware 04-2477008
-------- ----------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
530 Boston Post Road, Wayland, Massachusetts 01778
- ------------------------------------------------------ --------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (508) 358-7400
--------------
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $.01 par value
Common Stock Purchase Warrants
(Title of Class)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [ X ] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein and will not be contained in
definitive proxy or information statements incorporated by reference in Part
III of this Form 10-K or any amendment to this Form 10-K. [ ]
As of September 21, 1998, 5,481,606 shares of the registrant's Common Stock,
$.01 par value, were issued and outstanding. The aggregate market value of the
registrant's voting stock held by non-affiliates of the registrant as of
September 21, 1998, based upon the closing price of such stock on The NASDAQ
Stock Market on that date, was approximately $10,551,000.
DOCUMENTS INCORPORATED BY REFERENCE
Documents Form 10-K Reference
--------- -------------------
Proxy Statement for the 1998 Annual
Meeting of Shareholders Part III
PART I
------
ITEM 1. BUSINESS
- ------ --------
GENERAL
Candela Corporation (the "Company") develops, manufactures, and distributes
innovative clinical solutions that enable physicians and personal care
practitioners to treat selected cosmetic and medical problems using lasers,
cryosurgery, and other proven technologies. In addition, the Company operates
a skin care center and spa where specialized personal care services are
performed.
Since its inception in 1970, the Company has designed and marketed custom and
scientific lasers, and since 1984 has designed and marketed laser systems for
medical applications. In 1987, the Company commercially introduced its urology
laser system to treat kidney stones, and in 1988 it commercially introduced a
dermatology/plastic surgery laser system to treat vascular skin lesions.
In 1990, the Company commercially introduced a new dermatology/plastic surgery
laser system to treat pigmented lesions of the skin, such as age spots.
In 1994, the Company introduced an alexandrite laser for the treatment of
tattoos and for the treatment of Nevus of Ota and similar pigmented lesions.
In 1995, the Company introduced a dermatology/plastic surgery laser system to
treat leg veins. In 1996, the Company introduced the AlexLAZR(TM) for
treatment of pigmented lesions, such as age and sun spots and freckles.
In December 1996, the Company and Fotona, d.d., a company based in the Republic
of Slovenia, entered into an exclusive marketing agreement whereby the Company
has the rights to distribute the Fotona Skinlight(TM) Erbium:YAG laser in the
United States and Canada as well as the Far East, South America, South Africa
and some European countries. In January 1997, the Fotona Skinlight(TM) was
approved for marketing by the FDA for the cutting, vaporizing and coagulation
of soft tissue in dermatology and cosmetic surgery. In February 1997, the
Company commenced marketing the Fotona SkinPLUS(TM) Erbium:YAG, KTP/532 Laser
used in the treatment of facial veins and for skin resurfacing.
In the Fall of 1996, the Company announced FDA clearance to market its Dynamic
Cooling Device(TM), a device that significantly reduces pain during laser
surgery. The Dynamic Cooling Device(TM) (DCD) was designed in conjunction with
the University of California's Beckman Laser Institute and Medical Clinic
(BLIMC). The DCD is unique from other cooling devices in that it selectively
cools the top layers of the skin during laser treatments. The small compact
unit is available as an upgrade to the Candela ScleroPLUS laser and other
future systems.
The Dynamic Cooling Device(TM) is manufactured and sold pursuant to a
Technology License Agreement dated December 19, 1994, with the Regents of the
University of California (Regents). This License Agreement grants the Company
exclusive rights to dynamic cooling technology for use in conjunction with a
laser that the Company has a right to manufacture, sell, or upgrade for use in
dermatology and plastic surgery procedures that do not involve the shrinkage or
removal of collagen. On or about June 10, 1997, the Regents sent to the
Company a Notice of Partial Termination, alleging that the Company had
breached the due diligence requirements of the License Agreement and purported
to narrow the exclusive field of use granted to the Company. On or about June
13, 1997, the Company commenced litigation in the Massachusetts Superior Court
against the Regents seeking a declaration that the Technology License Agreement
remain in full force and effect and asserting claims for breach of the
Technology License Agreement. The Regents removed the action to the United
States District Court for the District of Massachusetts. On or about July 21,
1997, the Regents filed an Answer and Counterclaims against the Company
alleging that the Company breached and remains in breach of the Technology
License Agreement and sought
2
a declaratory judgment that the Regents have the right to terminate the
Technology License Agreement. On August 5, 1997, the Regents sent to the
Company another Notice purporting to terminate the Technology License
Agreement. The Company then pursued its declaratory judgment claim, and
defended against the Regents' counterclaims. After facts discovery in this
matter was substantially complete, the parties commenced settlement
negotiations. Though settlement negotiations are still proceeding and the
Company is optimistic about the outcome of the case. However, there can be no
assurance that the Company will prevail in these proceedings and in the event
the Regents were to prevail, the Company could lose its license to the dynamic
cooling technology.
In January 1997, the Company received a patent for its Elongated Spot
Handpiece, which provides physicians with the ability to treat linear lesions
and tattoos more precisely and with less purpura.
In the Spring of 1997, the FDA cleared for marketing, the Candela Skinscan(TM),
a microprocessor-driven skin scanning device designed for use with the
Skinlight(TM). The Skinscan(TM) ensures consistent, precise treatment for
facial and other soft tissue applications.
In December 1997, the Company began to market the GentleLASE(TM) system for the
treatment of vascular lesions. In July 1998, the Company received FDA
clearance for use of the GentleLASE(TM) for hair removal. The GentleLASE(TM)
is a high energy, long pulse alexandrite laser that features the Company's
proprietary dynamic cooling technology and enables the company to enter the
hair removal market.
The Company has a number of different lasers under development and plans to
continue to apply its technical expertise to develop systems for providing new
clinical solutions. The Company has entered into strategic alliances that are
aimed at acquiring new and complementary products to enhance the Company's
position in these markets.
In 1993, the Company entered into an agreement with Cryogenic Technology
Limited ("Cryotech") that gave the Company the exclusive worldwide (except the
United Kingdom) right to distribute the LCS 3000 and LCS 2000. The LCS 3000,
which has FDA clearance for ablation of prostatic tissue and liver metastases,
and the LCS 2000, which has FDA clearance for the ablation of liver metastases,
both employ the precise application of extreme cold to destroy diseased tissue.
In 1995, Spembly Medical Limited ("Spembly") entered into an agreement to
purchase the assets of Cryotech, including the rights to the LCS 3000 and LCS
2000. Subsequently, The Company and Spembly entered into an agreement under
which Spembly will manufacture a line of cryosurgical devices functionally
similar to the former Cryotech LCS 3000 and LCS 2000 which the Company will
market with exclusive rights in certain geographical areas. In 1996, a new
device, the CS5, was introduced. Under the agreement, the Company will have
exclusive world-wide rights to distribute these devices, excluding the United
Kingdom.
During l994, the Company's competitive position in the urology market was
strengthened with the addition of two FDA cleared cryogenic devices for the
ablation of prostatic tissue and liver metastases.
In the dermatology/plastic surgery market, the Company has pursued
opportunities to build on its strengths in worldwide distribution as well as to
acquire new technology. In 1993, the Company, through its wholly-owned
Japanese subsidiary, Candela KK, entered into an agreement with Laser
Industries, Ltd., that gives Candela KK the exclusive right to distribute Laser
Industries Nd:Yag and CO2 surgical lasers, surgical ultrasound aspirators, and
all related accessories for these products in Japan. Marketed under the
Sharplan tradename, this agreement leverages the Company's distribution
strength in Japan. Also, in 1994, the Company entered into an agreement to
acquire certain assets from Derma-Lase, Ltd. The assets acquired are
principally the rights to market FDA-cleared products which enable the Company
to market a broad line of lasers to treat tattoos and pigmented lesions. These
agreements leverage the Company's strengths in worldwide distribution and
service as well as its strong position in the dermatology/plastic surgery
market.
3
The Company markets and services its products in the United States through both
a direct sales force and independent distributors. Internationally, the
Company markets and services its products through regionally managed
independent distributors, except in Japan where Candela KK, in combination with
a network of independent distributors, markets and services the products, and
Spain, where the Company's subsidiary markets and services the products.
In August 1995, the Company incorporated a wholly-owned subsidiary, Candela
Skin Care Centers, Inc.(CSCC)to create a new service business that integrates
laser cosmetic procedures with spa, salon, health and fitness services under
one facility.
In October 1995, CSCC opened its first cosmetic laser center, occupying 2,690
square feet in a professional office building located in Framingham, MA. The
center was established principally as a pilot site to test the various
management systems and procedures and to formalize them for application at the
planned LaserSpas(TM). In June 1996, CSCC acquired an existing day spa in
Boston, MA formerly known as Le Pli at the Heritage on the Garden. The Company
then renovated and expanded the facility by adding an additional 2,200 square
feet of space to house the laser clinic. Upon completion of the renovations to
the Boston location, the Framingham location was consolidated into Boston. The
laser clinic in Boston is licensed by the Massachusetts Department of Public
Health and began treating patients in April 1997.
In February 1997, CSCC opened a full service LaserSpa(TM) in Scottsdale, AZ
which was intended to integrate salon, health, beauty, spa and laser cosmetic
services. In January 1998, after reassessing the funding requirements for
continuing the operation of this site, a decision was made to close the
facility. A national real estate broker is now listing the facility with the
intention of finding a tenant that will take over the lease of the facility.
BACKGROUND AND TECHNOLOGY
Lasers are optical devices which produce intense and narrow beams of light. A
laser consists of an active medium, such as a crystal, gas or liquid, that
amplifies light when excited by an external energy source (usually either an
optical source, such as a flashlamp, or an electric discharge). Light emitted
by the active medium is reflected inside the laser cavity, causing the
intensity of the light to increase and form usable output. Lasers are used in
an increasing number of diverse applications. The Company's aesthetic laser
systems provide a full range of applications for the treatment of vascular
lesions including red birthmarks, scars, warts, stretch marks, leg and facial
veins, pigmented lesions such as age spots and freckles, multi-colored tattoos
and hair removal.
Cryosurgical devices use subzero temperatures to destroy abnormal tissue. This
tissue is then left "in situ" to be sloughed or reabsorbed by the body.
Cryosurgical devices typically use liquid nitrogen or other refrigerants to
create a freezing environment. Cryosurgical devices are also used in an
increasing number of diverse applications, with procedures ranging from topical
dermatological treatments to the use of cryoprobes in minimally invasive
surgery.
COMMERCIALIZED MEDICAL PRODUCTS
The Company's research and development efforts, in conjunction with related
research done at leading medical institutions, have resulted in the development
and commercialization of the Company's medical laser systems. The Company has
also commercialized a number of laser systems and cryosurgical devices through
strategic alliances with other companies. The Company's medical products
include the following:
4
GentleLASE(TM). This long-pulse alexandrite laser offers precise non-invasive
- ----------
treatment of cosmetic skin conditions, such as the removal of excessive hair,
with integrated dynamic cooling for minimizing patient pain. GentleLASE
delivers high energy density and large laser spot, facilitating the treatment
of large areas. GentleLASE received FDA clearance for use in hair removal in
July, 1998.
ScleroPLUS(TM). This advanced laser system offers one of the widest array of
- --------------
wavelengths available for treatment of all vascular lesions and combines a
tunable, flashlamp pumped dye laser with the capabilities and applications of
the SPTL-1b laser. This laser is used for the treatment of conditions such as
leg and facial veins, port wine stains, stretch marks, scars, warts and other
vascular abnormalities. Six handpieces allow for precise and efficient
treatment of vessels, larger lesions or more cosmetic-oriented procedures.
This laser provides a repetition rate up to one pulse per second, resulting in
uniform heating/coagulation.
SkinPLUS(TM) Erbium:YAG, KTP/532 Laser. The SkinPLUS 2J dual laser was
- --------------------------------------
developed to offer the physician treatment capabilities in dermatology and
aesthetic surgery. The Erbium: YAG laser is a versatile and advanced laser
system used for skin ablation as an alternative to CO2 laser treatments. This
laser has the ability to vaporize tissue layer-by-layer with surgical precision
while minimizing thermal injury, thus shortening the healing and recovery time.
The KTP/532 laser is an additional module to the SkinPLUS system. The 532mm
wavelength is strongly absorbed by oxyhemoglobin and melanin and is used to
treat fine facial veins.
Skinscan(TM) Device. The Skinscan is a microprocessor-driven skin scanning
- -------------------
device designed for use with the SkinPLUS. The Skinscan promotes consistent,
precise treatment for facial and other soft tissue applications. Skinscan
positions the laser treatment beam over the skin for the physician, providing
precision and uniformity when treating large areas of skin during a single
session with a reduced laser procedure time.
SPTL-1b(TM) Vascular Lesion Laser. The SPTL-1b is used in the treatment of
- ---------------------------------
benign vascular lesions of the skin. These lesions are characterized by the
presence of abnormal blood vessels that lie beneath the surface of the skin
such as port wine stain birthmarks, congenital lesions that appear as light
pink lesions at birth and progressively darken and roughen with age,
telangiectasia or "spider veins", vascular lesions that develop with age on
many people over the age of 30, and hemangiomas, benign tumors made up of blood
vessels in a slightly elevated area of the skin.
AlexLAZR(TM). The AlexLAZR is a short pulse, rapid repetition alexandrite laser
- ------------
effectively treats multicolored tattoos, including greens and aqua. The
AlexLAZR also provides the physician with the ability to treat pigmented
lesions such as Nevus of Ota.
Dynamic Cooling Device(TM). The Dynamic Cooling Device is a device that
- --------------------------
selectively cools the top layers of the skin during treatment to significantly
reduce pain without decreasing the effectiveness of the laser treatments.
Elongated Spot Handpiece. This handpiece provides physicians with the ability
- ------------------------
to treat linear lesions and tattoos more precisely and with reduced purpura, by
avoiding unnecessary exposure to uninvolved tissue.
MDL 3000 LaserTripter(R). The Company's LaserTripter(R) model MDL 3000 is
- ------------------------
recognized as the gold standard of lasertripsy -- a safe and effective system
for fragmenting urinary and biliary stones without trauma to soft tissue.
Candela/Spembly Cryosurgical System CS-5. This system is a high-performance,
- ----------------------------------------
cost-effective cryosurgical system for the ablation of diseased prostate tissue
and liver metastases.
5
LCS 3000. The LCS 3000 is a cryosurgical system that is FDA approved for the
- --------
ablation of prostatic tissue and treatment of liver metastases. It employs up
to five independently controlled reusable probes to destroy diseased tissue by
the precise application of extreme cold. The probes are available in a variety
of shapes and sizes and are color coded for ease of use.
LCS 2000. The LCS 2000 is a cryosurgical system that is FDA approved for the
- --------
treatment of liver metastases. The LCS 2000 offers similar features to the LCS
3000, except that it operates with only two probes.
MEDICAL PRODUCTS UNDER DEVELOPMENT
The Company has developed, and continues to develop, new medical products and
new applications for its existing products. As the Company discovers potential
new medical applications of interest, it evaluates the applications and, if
appropriate, assembles a team to research and develop a new product or
application in cooperation with leading physicians and medical institutions.
The Company is currently conducting research on a number of applications. The
Company believes that its advanced research and engineering activities are
crucial in order to maintain and enhance the Company's business.
Where required, the Company is conducting these clinical research efforts under
Investigational Device Exemptions (IDE's) granted by the FDA. In many
instances, the Company must receive FDA clearance before commercializing new
products or applications. The Company believes that it can obtain such
clearances, but there can be no assurance that such clearances will be
received. See "Governmental Regulation."
MEDICAL RESEARCH AGREEMENTS
The Company has conducted joint research with physicians at Massachusetts
General Hospital, the New England Medical Center, University of California,
Beth Israel/Deaconess Hospital and elsewhere under research agreements. The
Company has also conducted joint laser research with MIT Lincoln Labs.
Generally, when the Company enters into research agreements, the Company has
rights to acquire exclusive licenses to any jointly developed technology and
may pay a royalty to the institution. The Company anticipates continuing joint
research and licensing arrangements with medical research institutions.
In addition to internally funded research projects, the Company has received a
number of Small Business Innovation Research ("SBIR") grants and contracts to
explore the feasibility of extending its laser technology to new applications.
Research is being conducted with several different types of lasers, including
pulsed dye lasers and solid state lasers.
PRODUCT MARKETING AND SERVICE
North America. The Company markets its medical systems through both a direct
- -------------
sales force and independent distributors. With the exception of the geographic
areas covered by independent distributors, the Company has direct sales
representatives with territories covering all of North America. The
independent distributors, who have significant medical laser distribution
experience, have exclusive arrangements for their geographic areas.
The Company's focus is on optimizing patient care and physician productivity.
The Company maintains a staff of nurse clinicians to train laser system
customers. In addition, the Company conducts and participates in regional
workshops where physicians knowledgeable in the use of the Company's systems
instruct other doctors in their use.
6
Promotional activities conducted by the Company include trade advertising,
direct mail, workshops, presentations at trade shows, and in-vitro
demonstrations at medical conventions.
International. The Company sells a significant portion of its medical systems
- -------------
outside of the United States. The Company has wholly-owned Japanese and
Spanish subsidiaries that coordinate the activities of several distributors and
businesses. In addition, the Company has a branch office in The Netherlands to
develop and maintain independent distributor relationships in Europe, the
Middle East and Africa.
Sales by foreign subsidiaries and sales from the United States to international
customers, for each of the last three fiscal years was:
1998 1997 1996
----- ---- -----
International revenue:
Total $19,777,000 $18,508,000 $16,068,000
As percentage of revenue 53% 52% 53%
See also Note 10 to the Company's Consolidated Financial Statements.
Service. The Company's principal service center and parts depot is located at
- -------
its Wayland, Massachusetts, headquarters. In addition, the Company has direct
service representatives throughout the United States and parts depots at its
wholly-owned subsidiaries in Japan and Spain. The Company's independent
distributors maintain parts depots and service representatives adequate to
cover their installed systems and have primary responsibility to service such
systems. The Company's recommended preventive maintenance, coupled with
continuing technical education for service representatives, help to ensure
product reliability.
SKIN CARE CENTER SERVICE
The Company has marketed skin care services through its wholly-owned
subsidiary, CSCC. These services include laser cosmetic procedures as well as
spa, salon and health and fitness services. The Company currently operates one
laser/cosmetic center in Boston, Massachusetts, which is currently for sale.
Revenues for CSCC for each of the last three fiscal years was:
1998 1997 1996
---- ---- ----
$2,703,000 $2,243,000 $2,149,000
MANUFACTURING AND SUPPLIERS
The Company's manufacturing operations consist principally of the assembly and
testing of components purchased from outside suppliers. The Company also
manufactures certain power supplies and other subassemblies used in its
products. The Company depends upon a number of outside suppliers for the
components that it has used to assemble laser systems produced to date and for
products that it may manufacture in the future. In addition, the Company
relies upon a single source for its cryosurgical products and certain
components. To date, the Company has not experienced, nor does it expect to
experience in the future, significant delays in obtaining dyes, optical and
electro-optical components, electronic or any other components and raw
materials for its products, most of which are available from multiple well-
established sources. There can be no assurance, however, that the Company's
supplies of components, raw materials and cryosurgical products will continue
to be available in sufficient quantities and in a timely manner in the future.
7
COMPETITION
Competition in the medical device industry is intense, and technological
developments are expected to continue at a rapid pace. The Company utilizes
proprietary technology, product features, performance and price in addition to
its market reputation as competitive methods, depending upon the product,
market or geographic area in which it is competing. The Company competes with
other manufacturers, some of which may have greater financial, marketing, and
technical resources than the Company, as well as with alternative medical
technologies. In addition, some companies have developed, and other
established companies may attempt to develop products with medical applications
similar to the Company's systems.
In addition, the Company's CSCC operation faces a host of competitors including
hair salons, health spas, massage therapists, aestheticians, health and fitness
clubs, personal trainers, dermatologists, plastic surgeons, cosmetic laser
centers and cosmetic retailers. Further, even if the Company is able to
successfully compete, there can be no assurance that it would be able to do so
in a profitable manner.
PATENTS AND PROPRIETARY INFORMATION
The Company owns United States and foreign patents for its urology, benign
vascular and pigmented lesion dermatology/plastic surgery laser systems and
United States patents for its endoscopes. The Company also has several United
States and foreign patents and pending patent applications for other medical
laser systems. The Company treats its design and technical data as
confidential, and relies on nondisclosure safeguards, such as confidentiality
agreements, laws protecting trade secrets and noncompetition agreements to
protect its proprietary information. There can be no assurance, however, that
these measures will adequately protect the Company's technology or that others
will not independently develop such technological expertise. See Item 3,
"Legal Proceedings" for information relating to a dispute involving a license
relationship.
The Company is a licensee under patent license agreements that grant the
Company rights to use certain laser technologies and applications. Under these
license agreements, the Company has paid, and continues to pay, royalties.
Under the federal government's SBIR program, the Company retains rights to any
invention and the ownership of all data developed under such program. In
return, the government receives a royalty-free license on any patent for
federal government use and it reserves certain other rights, including the
right to require the Company to license others to use the technology in certain
limited circumstances.
GOVERNMENTAL REGULATION
The Company's products are subject to governmental regulation in the United
States and in other countries. In order to manufacture, clinically test and
market products for human diagnostic and therapeutic use, the Company must
comply with mandatory regulations and safety standards established by the FDA
and comparable state and foreign regulatory agencies. Typically, products must
meet regulatory standards as safe and effective for their intended use prior to
being marketed for human applications. The clearance process is expensive and
time consuming, and no assurance can be given that any agency will grant
clearance for the sale of the Company's products or that the length of time the
process will require will not be extensive. The Company has met FDA
requirements under the 510(k) procedure for the products it is currently
marketing.
8
There are two principal methods by which FDA regulated medical devices may be
marketed in the United States. One method is to obtain an FDA pre-market
notification filing under Section 510(k) of the Food, Drug and Cosmetics Act.
Applicants under the 510(k) procedure must demonstrate that the device for
which clearance is sought is substantially equivalent to devices already on the
market pursuant to a 510(k) procedure or prior to the medical device
legislation of 1976. The review period for a 510(k) application is 90 days from
the date of filing the application, although such review periods have often
been extended. Applications filed pursuant to 510(k) are often subject to
questions and requests for clarification that can extend the review period
beyond the initial 90 day period. Marketing of the product must be deferred
until written clearance is received from the FDA. In some instances, an
investigative device exemption ("IDE")is required for clinical trials in order
to obtain a 510(k) notification.
The alternate method, where section 510(k) is not available, is to obtain
premarket approval ("PMA") from the FDA. Under the PMA procedure, the
applicant must obtain an IDE before beginning the substantial clinical testing
that is required in order to determine safety and efficacy of the product. The
preparation of a PMA application is significantly more complex and time
consuming than that of the 510(k) application. The review period for a PMA
application is 180 days from the date of filing, although such review times
have been substantially extended. The FDA often responds with requests for
additional information or clinical reports, which can extend the review period
beyond the initial 180 day period.
In addition, the Company is required to obtain FDA approval prior to conducting
clinical studies with certain of the medical laser systems it has under
development. All of these products will require filing of a 510(k) or PMA for
commercialization of the product, and some may require the filing of an IDE
with the FDA. The Company is currently approved to conduct clinical studies
under the IDE regulations. There can be no assurance that the FDA will grant
necessary approvals for the Company's new products or that the process to
obtain such approvals will not be excessively expensive or lengthy. The
failure to receive requisite approvals for the Company's products or processes,
when and if developed, or significant delays in obtaining such approvals would
prevent the Company from commercializing new products as anticipated and would
have a materially adverse effect on the business of the Company.
The FDA also imposes various requirements on manufacturers and sellers of
products under its jurisdiction, such as labeling, manufacturing practices,
record keeping and reporting requirements. The FDA also may require postmarket
testing and surveillance programs to monitor a product's effects.
The Company is also subject to regulation under the Radiation Control for
Health and Safety Act administered by the Center for Devices and Radiological
Health ("CDRH") of the FDA, which requires laser manufacturers to file new
product and annual reports, to maintain quality control, product testing and
sales records, to incorporate certain design and operating features in lasers
sold to end-users and certify and label each laser sold to an end-user as
belonging to one of four classes, based on the level of radiation from the
laser that is accessible to users. Various warning labels must be affixed and
certain protective devices installed, depending on the class of product. The
CDRH is empowered to seek fines and other remedies for violations of the
regulatory requirements. The Company believes that it has complied in all
material respects with the applicable CDRH requirements.
Foreign sales of the Company's laser systems are subject in each case to the
regulatory requirements of the FDA and the recipient country. These vary
widely among the countries and may include technical approvals, such as
electrical safety, as well as the demonstration of clinical efficacy. The
Company is currently working to meet foreign country regulatory requirements
for certain of its products. There can be no assurance that additional
approvals will be obtained.
9
RESEARCH AND DEVELOPMENT
During the past three fiscal years, the Company spent the following amounts on
Company-sponsored and federal government-sponsored SBIR research:
1998 1997 1996
---- ---- ----
Company-sponsored research and
development $2,399,000 $2,488,000 $1,818,000
SBIR-sponsored research and
development $ 155,000 $ 108,000 $ 147,000
(The costs of SBIR research are included in cost of sales in the Income
Statement.)
Under the SBIR Program, a portion of a federal agency's research and
development budget is awarded to small businesses that have 500 or fewer
employees. There are two phases to an SBIR award: Phase I provides funding for
determining the scientific and technical merit and feasibility of a proposed
idea; and Phase II provides funding to further develop a proposed idea, taking
into consideration the scientific and technical merit and feasibility evidenced
by Phase I results. After completion of the two phases using government funds,
the Company is expected to commercialize the new product using funds generated
by the Company or funds raised through alternate financing means.
CUSTOMERS
The Company's customers include distributors, hospitals, medical doctors and in
the case of CSCC, individual consumers. The Company is not dependent upon any
single customer. See Note 10 to the Company's Consolidated Financial
Statements for a description of revenue generated by region.
EMPLOYEES
As of June 27, 1998, the Company had 217 employees of which 19 were in
research, development and engineering, 35 were in manufacturing and quality
assurance, 18 were in service, 24 were in sales and marketing, 18 were in
finance and administrative positions, 83 were in the clinic and health spa
subsidiary and 20 were in the international sales/service subsidiaries. None
of the Company's employees are represented by a union, and the Company believes
its relationship with its employees is good.
NEW ACCOUNTING PRONOUNCEMENTS
In June 1997, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standard No. 130 Reporting Comprehensive Income ("SFAS
130") which establishes standards for reporting and display of comprehensive
income and its components (revenue, expenses, gains and losses) in a full set
of general purpose financial statements. Management is currently evaluating the
effects of this change on its reporting of income. The Company has adopted SFAS
130 for its fiscal year ending July 3, 1999.
Also in June 1997, the FASB issued Statement of Financial Accounting Standard
No. 131 ("SFAS 131"), "Disclosure about Segments of an Enterprise and Related
Information." Based on the management approach to segment reporting, SFAS No.
131 establishes requirements to report selected segment information quarterly
and to report entity-wide disclosures about products and services, major
customers and the countries in which the entity holds material assets and
reports material revenue.
10
The Company has adopted SFAS No. 131 for its fiscal year ending July 3, 1999,
and management is currently evaluating its effects on the Company's reporting
of segment information.
YEAR 2000 COMPLIANCE
The Company has established a committee to assess the implications of Year 2000
issues on operations, from information and financial systems to each aspect of
its manufacturing processes, in order to determine the extent to which the
Company may be adversely affected by Year 2000 issues. Indications based on
the internal assessment, which is approximately 50% complete, reveals minimal
impact of Year 2000 issues on the Company. The Company expects to finish the
assessment process by December 1998. Though limited testing of systems has
been performed to date, the Company has developed its systems and products with
Year 2000 in mind, thus minimizing the impact of the change. The Company may
conduct further testing and/or an external audit following the conclusion of
its internal assessment. To date there has been a limited number of hours
devoted to Year 2000 issues, with no additional cost expended in systems
upgrades directly relating to Year 2000 issues. Present estimates for further
expenditures of both employee time and expenses to address Year 2000 issues are
between 40 and 120 hours and between $0 and $20,000, respectively. All
expenditures will be expensed as incurred and they are not expected to have a
significant impact on the Company's ongoing results of operations.
The Company has undertaken an informal survey of its suppliers' Year 2000
compliance status with responses indicating Year 2000 compliance at this time.
Further, the Company has conferred with significant customers to assure that
various systems used for data and information exchanges between them will be
compatible following December 31, 1999.
Based on its assessments to date, the Company believes it will not experience
any material disruption as a result of Year 2000 issues in internal
manufacturing processes, information processing or interface with key
customers, or with processing orders and billing. However, if certain critical
third party providers, such as those supplying electricity, water or telephone
service, experience difficulties resulting in disruption of service to the
Company, a shutdown of the Company's operations at individual facilities could
occur for the duration of the disruption.
At present, the Company has not developed contingency plans but intends to
determine whether to develop any such plan by January 1999. There can be no
assurance that Year 2000 issues will not have a material adverse effect on the
Company's business, results of operation and financial condition.
EXECUTIVE OFFICERS
The current executive officers of the Company are as follows:
Name Age Position
- ---- --- ---------
Gerard E. Puorro 51 President, Chief Executive Officer and Director
F. Paul Broyer 49 Senior Vice President of Finance and
Administration, Chief Financial Officer, and Treasurer
James C. Hsia, Ph.D 52 Senior Vice President, Research
William D. Spies 48 Senior Vice President of Marketing, Sales and
Service
Jay D. Caplan 36 Vice President, Operations
William B. Kelley 43 Vice President, North American and Latin American
Sales
William McGrail 37 Vice President of Development Engineering
Toshiro Mori 46 Vice President, President of Candela KK
Robert Wilber 40 Vice President - Worldwide Service
11
Executive officers of the Company are elected by the Board of Directors on an
annual basis and serve until their successors are duly elected and qualified,
subject to earlier removal by the Board of Directors. There are no family
relationships among any of the executive officers or directors of the Company.
Mr. Puorro was appointed a Director of the Company in September 1991. Mr.
Puorro has been President and Chief Executive Officer of the Company since
April 1993. From April 1989 until April 1993, he was Senior Vice President and
Chief Financial Officer of the Company. He was elected Chief Operating Officer
in December 1992. Prior to joining the Company, and since 1982, he was Vice
President and Controller at Massachusetts Computer Corporation. Mr. Puorro
became acting Chief Executive Officer of Candela Skin Care Centers, Inc. in
June 1997.
Mr. Broyer was appointed Senior Vice President of Finance and Administration,
Chief Financial Officer, and Treasurer in July, 1998. Mr. Broyer joined the
Company in October 1996 as Vice President and Chief Financial Officer. Prior
to joining the Company, Mr. Broyer held the position of Vice President Finance
at Integrated Genetics from 1994 to 1996. From 1987 until 1994 Mr. Broyer was
Corporate Controller for Laserdata, Inc. and held earlier positions with Avatar
Technologies and Data General Corporation.
Dr. Hsia has been Senior Vice President, Research, of the Company since July
1991. He has been with the Company since October 1985, and was previously Vice
President, Research and Development. Prior to joining the Company, and since
1982, he was Vice President, Research and Development at Laser Science, Inc.
Mr. Spies joined Candela in July, 1998, as Senior Vice President of Marketing,
Sales, and Service. Prior to joining the Company, and since 1996, Mr. Spies
held the position of Director, Business Development with the Cordis medical
device unit of Johnson & Johnson. From 1988 to 1996 Mr. Spies held the
positions of Executive Vice President/General Merchandise Manager and Vice
President Sales and Marketing with Seiko Optical Products. Previously Mr.
Spies held a position with Corning, Inc.
Mr. Caplan was appointed Vice President, Operations in February 1997, after
serving as Vice President, Manufacturing since December 1995. He has been with
the Company since September 1988 and was previously Senior Director, Corporate
Planning/Business Development. From 1988 to 1993, Mr. Caplan held the
positions of Product Director, International Controller, Manager, Financial
Planning and Analysis and Planning Associate. Prior to joining the Company,
Mr. Caplan held positions at Xerox Corporation and the United States Air Force.
Mr. Kelley was named Vice President of North American and Latin American Sales
in July, 1998. Mr. Kelley was previously Vice President, North American Sales
and Service, from April 1993 through June, 1998. From January 1993 until April
1993 he was Vice President, Domestic Sales. He has been with the Company since
1987 and previously held the positions of National Sales Manager and Eastern
Regional Sales Manager. Prior to joining the Company, Mr. Kelley held a number
of sales and sales management positions in the medical industry.
12
Mr. McGrail was named Vice President of Development Engineering in July,
1998. Previously, Mr. McGrail served in the position of Director of
Engineering since August, 1994. From 1987 to 1992, he held the positions of
Senior Software Engineer and Software Design Engineer. Prior to joining
Candela, Mr. McGrail was employed with Raytheon Corporation.
Mr. Mori was named Vice President, President of Candela K.K. in July, 1998,
after serving as President and Representative Director of Candela K.K. since
September, 1996. Previously Mr. Mori held the positions of Director of Candela
K.K. from September, 1992 to September, 1996, and General Manager from
September, 1989 to September, 1992. From 1976 to 1989, he was employed by
Sansui Electric Co. Ltd. in Tokyo.
Mr. Wilber was appointed Vice President, Worldwide Service in August 1997,
after serving as Director of Worldwide Service since October 1993. He has been
with the Company since September of 1989 and was previously a Finance Group
Director. From 1989 to 1992 Mr. Wilber held the positions of International
Accounting Manager, Customer Service Manager and Director of Financial Planning
and Analysis. Prior to joining the Company, Mr. Wilber held positions at Sony
Corporation of America, Massachusetts Computer Corporation and National
Semiconductor/Data Terminal Systems.
ITEM 2. PROPERTIES
- ------ ----------
The Company leases a facility totaling approximately 35,000 square feet for its
operations in Wayland, Massachusetts, which is located approximately 20 miles
west of Boston. The lease on this facility was amended in April 1998 to extend
the expiration date to March 2003. Management of the Company believes that its
current facilities are suitable and adequate for its near-term needs.
The Company's subsidiary, Candela Skin Care Centers, Inc, currently leases the
following facilities:
1) Candela Skin Care Center of Scottsdale, Inc., 7,555 square feet located
at 6939 E. Main Street, Scottsdale, AZ. The lease on this facility is for a
period of ten years, expiring on June 30, 2006, with a provision for two five-
year extensions;
2) Candela Skin Care Center of Boston, Inc., 20,728 square feet located at
28 Arlington Street, Boston, MA. The lease on this facility is for a period of
15 years, and commenced on June 1, 1994; and
3) Candela Skin Care Centers, Inc., 2,000 square feet located at 79 Newbury
Street, Boston, MA. The lease on this facility is for a period of 12 months,
and commenced on October 1, 1997.
ITEM 3. LEGAL PROCEEDINGS
- ------ -----------------
The Company's Dynamic Cooling Device(TM) (DCD) is manufactured and sold
pursuant to a Technology License Agreement dated December 19, 1994, with the
Regents of the University of California (Regents). This License Agreement
grants the Company exclusive rights to dynamic cooling technology for use in
conjunction with a laser that the Company has a right to manufacture, sell, or
upgrade for use in dermatology and plastic surgery procedures that do not
involve the shrinkage or removal of collagen. On or about June 10, 1997, the
Regents sent to the Company a Notice of Partial Termination, alleging that the
Company had breached the due diligence requirements of the License Agreement
and purported to narrow the exclusive field of use granted to the Company. On
or about June 13, 1997, the Company commenced litigation in the Massachusetts
Superior Court against the Regents seeking a declaration that the Technology
License Agreement remain in full force and effect and asserting claims for
breach of the Technology License
13
Agreement. The Regents removed the action to the United States District Court
for the District of Massachusetts. On or about July 21, 1997, the Regents
filed an Answer and Counterclaims against the Company alleging that the Company
breached and remains in breach of the Technology License Agreement and sought a
declaratory judgment that the Regents have the right to terminate the
Technology License Agreement. On August 5, 1997, the Regents sent to the
Company another Notice purporting to terminate the Technology License
Agreement. The Company then pursued its declaratory judgment claim, and
defended against the Regents' counterclaims. After facts discovery in this
matter was substantially complete, the parties commenced settlement
negotiations. Though settlement negotiations are still proceeding and the
Company is optimistic about the outcome of the case. However, there can be no
assurance that the Company will prevail in these proceedings and in the event
the Regents were to prevail, the Company could lose its license to the dynamic
cooling technology.
From time to time, the Company is a party to various legal proceedings
incidental to its business. The Company believes that none of such other
presently pending legal proceedings will have a material adverse effect upon
its financial position, results of operation, or liquidity.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
- ------ ---------------------------------------------------
During the fourth quarter of fiscal 1998, no matters were submitted to a vote
of security holders of the Company through the solicitation of proxies or
otherwise.
14
PART II
-------
ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER
- ------ -----------------------------------------------------------------
MATTERS
-------
The Company's common stock trades on The NASDAQ Stock Market under the symbol
"CLZR."
At September 21, 1998, there were 406 holders of record of the Company's common
stock and the last sales price of the Company's common stock was $3 15/16 on
that day.
The following table sets forth quarterly high and low prices of the common
stock for the indicated fiscal periods:
1998 1997
------- --------
High Low High Low
------- -------- ------- -------
First Quarter $ 6 $ 4 1/4 $ 8 5/8 $4 5/8
Second Quarter 7 1/8 4 1/4 7 3/8 4 5/8
Third Quarter 5 1/2 3 1/4 9 1/16 5 3/4
Fourth Quarter 4 5/16 2 13/16 7 3/4 5
The Company has never paid a cash dividend and has no present intention to pay
cash dividends in the foreseeable future. The Board of Directors currently
intends to retain any future earnings for use in the Company's business.
ITEM 6. SELECTED FINANCIAL DATA
- ------ -----------------------
The table set forth below contains certain financial data for each of the last
five fiscal years of the Company. This data should be read in conjunction with
the detailed information, financial statements and notes thereto, as well as
Management's Discussion and Analysis of Financial Condition and Results of
Operations included elsewhere herein.
(in thousands, except per share data) For the Year Ended:
Statement of Operations Data: 1998 1997 1996 1995 1994
- ----------------------------- ---- ---- ---- ---- ----
Revenue $37,025 $35,505 $30,413 $ 28,244 $29,820
Gross profit 16,318 16,855 13,580 12,376 13,765
Research and development expense 2,399 2,488 1,818 3,733 3,810
Selling, general & administrative expenses 15,271 13,680 9,873 10,246 9,241
Restructuring Costs 2,609 0 0 0 0
Income (loss) from operations (3,961) 687 1,889 (1,603) 714
Net income (loss) (4,452) 238 1,245 (1,536) 655
Basic earnings(loss)per share (.81) .04 .23 (.29) .13
Diluted earnings(loss)per share (.81) .04 .22 (.29) .13
Weighted average shares outstanding 5,479 5,398 5,321 5,288 5,206
Adjusted weighted average
shares outstanding 5,479 5,673 5,652 5,288 5,208
June 27, June 28, June 29, July 1, July 2,
Baance Sheet Data: 1998 1997 1996 1995 1994
- ------------------- ---- ---- ---- ---- ----
Working capital $ 2,639 $ 7,032 $ 8,608 $ 8,033 $ 9,109
Total assets 22,604 24,837 19,334 16,832 20,447
Short-term debt 3,052 1,000 - - -
Current portion of long-term debt 597 827 708 470 102
Long-term debt 887 1,519 557 476 223
Stockholders' equity 5,395 10,246 9,965 9,086 10,566
15
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
- ------ ---------------------------------------------------------------
RESULTS OF OPERATIONS
---------------------
RESULTS OF OPERATIONS
FISCAL 1998 COMPARED TO FISCAL 1997
- -----------------------------------
Total revenue for fiscal 1998 and fiscal 1997 are as follows:
(in thousands) 1998 1997 $ Change % change
-------- -------- -------- ---------
Laser operations $34,322 $33,262 $1,060 3.2%
Skin care centers 2,703 2,243 460 20.5%
------- ------- ------ ----
Total revenue $37,025 $35,505 $1,520 4.3%
======= ======= ====== ====
Revenues increased due to significant third and fourth quarter shipments of the
Company's new GentleLASE(TM) system and increased volume in the Company's
Spanish subsidiary. Sclerolaser(TM) and AlexLAZR(TM) shipments continue to be
strong. These increases were partially offset by a sales decline in the
Japanese subsidiary, resulting from the devaluation of the Japanese Yen.
International revenue as a percentage of total revenue represented 53% of
revenue in fiscal 1998, compared to 52% in fiscal 1997. (See footnote 10).
The Company's gross margin decreased to 44% in fiscal 1998 from 48% in fiscal
1997 due to the negative effect of currency devaluation on the Japanese
subsidiary and a decrease in gross margins of the skin care centers, the result
of increased medical procedure costs. Gross margins from the laser operations
decreased to 47% in fiscal 1998, in comparison to 50% in fiscal 1997.
Research and development spending decreased $89,000, or 4%, to $2,399,000 in
fiscal 1998 from $2,488,000 in fiscal 1997. As a percent of revenue, research
and development spending decreased to 6% in fiscal 1998 from 7% in fiscal 1997.
The Company continues to build on its strengths in the dermatology markets and
internal development efforts continue to be focused accordingly. The Company
expects expenditures for research and development to be between 5% and 10% of
annual revenue in future periods.
Selling, general and administrative expenses increased 12% to $15,271,000 in
fiscal 1998 from $13,680,000 in fiscal 1997, as a result of significant charges
incurred in the second quarter for legal fees, consulting expenses and an
additional provision for potentially uncollectible accounts and notes
receivable from a domestic distributor. Selling, general and administrative
expenses as a percentage of total revenue increased to 41% in fiscal 1998 from
39% in fiscal 1997.
During the second quarter ended December 27, 1997, a restructuring charge was
recorded against income in the amount of $2,609,000. This charge represents
the anticipated costs associated with closing the Scottsdale, Arizona,
LaserSpa(TM), including costs of maintaining the unused facility, the write-off
of leasehold improvements an impairment write-down of the equipment at the
site. Charges against the reserve for the year ended June 27, 1998 total
$614,000, leaving a reserve balance of $1,995,000 at that date.
16
Interest income decreased to $42,000 in fiscal 1998 from $84,000 in fiscal 1997
as a result of a decrease in average cash balances. Interest expense increased
to $235,000 in fiscal 1998 from $107,000 in fiscal 1997 as a result of the
increased level of both debt and lease financing. Other expenses in fiscal 1998
of $123,000 and other expense in fiscal 1997 of $26,000 results primarily from
foreign currency transactions.
Included in the Company's consolidated net income are results of operations of
its wholly-owned subsidiary, Candela Skin Care Centers, Inc.(CSCC), consisting
of a net loss of $5,539,000 in fiscal 1998 compared to a net loss of $3,448,000
for fiscal 1997. The increase in net loss results from the creation of the
$2,609,000 reserve for restructuring charged in the second quarter of 1998.
The provision for income taxes in fiscal 1998 results from taxable income from
the Company's subsidiaries in Spain and Japan.
As a result of the foregoing factors, the Company realized a net loss of
$4,452,000, or $0.81 per share in fiscal 1998, compared to net income of
$238,000 or $0.04 per share in fiscal 1997.
FISCAL 1997 COMPARED TO FISCAL 1996
- -----------------------------------
Total revenue for fiscal 1997 and fiscal 1996 are as follows:
(in thousands) 1997 1996 $ Change % change
-------- -------- -------- ---------
Laser operations $33,262 $28,264 $4,998 17.7%
Skin care centers 2,243 2,149 94 4.4%
------- ------- ------ ----
Total Revenue $35,505 $30,413 $5,092 16.7%
======= ======= ====== ====
The increase in revenues for laser operations reflects significant shipments of
the Company's leg vein device, the Sclerolaser(TM), the AlexLAZR(TM), used for
removal of tattoos and pigmented lesions, and the Erbium YAG laser, used for
skin resurfacing. Revenues for the Skin Care Centers reflect increases
resulting from the opening of the new center in Scottsdale, AZ, and slight
increases from the Boston, MA, center. International revenue as a percentage
of total revenue represented 52% of revenue in 1997, compared to 53% in fiscal
1996.
Gross margin increased to 48% in fiscal 1997 from 45% in fiscal 1996,
reflecting volume increases in the Company's new dermatology products offset in
part by greater costs associated with the laser centers.
Research and development spending increased 37% to $2,488,000 in fiscal 1997
from $1,818,000 in fiscal 1996. As a percentage of revenue, research and
development spending increased to 7% in fiscal 1997 from 6% in fiscal 1996.
The Company continues to build on its strengths in the urology and dermatology
markets and internal development efforts were refocused accordingly.
Selling, general and administrative expenses increased 39% to $13,680,000 in
fiscal 1997 from $9,873,000 in fiscal 1996, as a result of increased spending
associated with the establishment of the skin care centers and increased
marketing expenses. Selling, general and administrative expenses as a
percentage of total revenue increased to 38% in fiscal 1997 from 32% in fiscal
1996.
17
Interest income decreased to $84,000 in fiscal 1997 from $93,000 in fiscal 1996
as a result of a decrease in average cash balances. Interest expense increased
to $107,000 in fiscal 1997 from $49,000 in fiscal 1996 as a result of an
increased level of both debt and lease financing. Other expenses in fiscal 1997
of $26,000 and other expense in fiscal 1996 of $207,000 results primarily from
foreign currency transactions.
Included in the Company's consolidated net income are results of operations of
its wholly-owned subsidiary, CSCC, consisting of a net loss of $3,448,000 in
fiscal 1997 compared to a net loss of $687,000 for fiscal 1996, its first year
of operation. This increase in net loss is primarily due to various start-up
costs associated with CSCC's facilities, all of which were opened in fiscal
1997.
The provision for income taxes in fiscal 1997 results primarily from taxable
income in the Company's subsidiary in Japan. Income taxes provided for in
fiscal 1997 reflect an effective tax rate of 63%. This tax rate includes both
foreign taxes, which generally are higher than those in the U.S., and state
income taxes.
As a result of the foregoing factors, the Company realized net income of
$238,000, or diluted earnings per share of $0.04 per share in fiscal 1997,
compared to net income of $1,245,000, or diluted earnings per share of $0.22
per share in fiscal 1996.
LIQUIDITY AND CAPITAL RESOURCES
Cash and cash equivalents at June 27, 1998, decreased to $1,615,000 from
$2,674,000 at June 28, 1997. This decrease resulted primarily from operating
losses incurred at CSCC and a reduction of accounts payable. Net cash used for
operating activities amounted to $1,864,000 in fiscal 1998 in comparison to
cash provided of $408,000 in fiscal 1997.
In June 1998, the Company borrowed 50,000,000 yen ($355,000) on a note against
a customer's note receivable using a short-term note. As of June 27, 1998, the
liability was $352,000, as converted at the year-end exchange rate, bearing
interest at 1.825%. This note was paid on the due date of August 17, 1998.
During fiscal 1997, the Company secured a $3,500,000 Line of Credit with a
major bank expiring on December 1, 1998. The Line of Credit bears interest at 1%
over the bank's prime lending rate and is collateralized by total domestic
accounts receivable, international accounts receivable covered by credit
insurance, inventory and a pledge of the stock of CSCC. The Company had
utilized $2,700,000 of the credit facility at June 27, 1998. Also during fiscal
1997, the Company borrowed 75,000,000 yen ($677,000) on a two-year 1.745% note
with a foreign bank. As of June 27, 1998, the value of this liability is
$294,000, converted at the year-end exchange rate. The Company's remaining
short-term and long-term debt is comprised solely of capital lease obligations,
which were $362,000 and $828,000, respectively, at June 27, 1998, versus
$346,000 and $1,149,000 at June 28, 1997.
The Company expects current cash flow, in conjunction with the remaining cash
available under the Line of Credit, to enable it to operate for the foreseeable
future.
The Company's experience has been to renew its bank financing arrangement
annually, and management believes the Company will be able to renew the above
line of credit on acceptable terms, however there is no assurance that they will
be successful. In addition, the Company continues to evaluate alternative
sources of financing, including both debt and equity arrangements, to ensure the
Company has sufficient liquidity to fund operations throughout the next year.
Should these alternatives not be possible, there could be material adverse
implications for the Company's financial position and operations.
18
CAUTIONARY STATEMENTS
In addition to the other information in this Annual Report on Form 10-K, the
following cautionary statements should be considered carefully in evaluating
the Company and its business. Statements contained in this Form 10-K that are
not historical facts (including without limitation, statements concerning
anticipated operational and capital expense levels and such expense levels
relative to the Company's total revenues) and other information provided by the
Company and its employees from time to time may consist of "forward-looking"
information, as that term is defined by (i)the Private Securities Litigation
Reform Act of 1995 (the "Act") and (ii)in releases made by the Securities and
Exchange Commission (the "SEC"). The factors identified in the cautionary
statements below, among other factors, could cause actual results to differ
materially from those suggested in such forward-looking statements. The
cautionary statements below are being made pursuant to the provisions of the
Act and with the intention of obtaining the benefits of the "safe harbor"
provisions of the Act.
VARIABILITY OF QUARTERLY OPERATING RESULTS. The Company's quarterly operating
results may vary significantly from quarter to quarter, depending upon factors
such as the timing of product sales, the timing of expenditures in anticipation
of future product orders, the introduction and market acceptance of new
products, effectiveness in managing manufacturing processes, changes in cost
and availability of labor and product components, order cancellations, the
budgetary cycles of its customers, the timing of regulatory approvals and the
cost of operating the LaserSpa(TM) owned by the Company's wholly-owned
subsidiary, Candela Skin Care Centers, Inc.. The Company's ability to
accurately forecast future revenues and income for any period is necessarily
limited, and any forward-looking information provided from time to time by the
Company represents only management's then-best current estimate of future
results or trends, and actual results may differ materially from those
contained in the Company's estimates.
POTENTIAL VOLATILITY OF STOCK PRICE. There has been significant volatility in
the market price of securities of companies in the medical device industry.
Factors such as announcements of new products by the Company or its
competitors, quarterly fluctuations in the financial results of the Company or
its competitors, shortfalls in the Company's actual financial results compared
to results previously forecast by stock market analysts, conditions in the
medical device industry and the financial markets and the economy generally
could cause the market price of the Company's securities to fluctuate
substantially and may adversely affect the price of the Company's securities.
RISKS ASSOCIATED WITH INTERNATIONAL OPERATIONS. A significant portion of the
Company's revenues are attributable to international operations and those
revenues are likely to continue to represent a significant portion of the
Company's revenues in future periods. The Company's international business and
financial performance may be adversely affected by a number of factors,
including without limitations to fluctuations in exchange rates, tariffs and
other trade barriers, adverse tax regulation, and adverse political and
economic conditions. Adverse effects on the Company's international operations
may have materially adverse effects on the Company's overall financial
condition and operating results.
19
BUSINESS STRATEGIC DEVELOPMENT. While continuing to expand and diversify its
core cosmetic and surgical laser equipment business, the Company embarked on a
new business strategy of opening combined spa and laser cosmetic skin care
centers. Currently the Company operates a combined spa/skin care facility in
Boston, Massachusetts, created by combining the Company's skin care center
previously located in Framingham, Massachusetts, with the spa in Boston. A
Combined spa/skin care facility located in Scottsdale, Arizona, was closed in
December 1997. While the Company continues to operate the Boston facility, it
has made the decision to sell the assets of both the Scottsdale and the Boston
facilities. In March 1998, the Company negotiated with a California-based
aesthetic/cosmetic services group for the sale of both facilities. Since these
negotiations failed to consummate the sale of the facilities to this group, the
Company made the decision to place the sale/sublease of the facilities with a
national real estate broker. The Company anticipates that the sale of both
facilities will be finalized within the next fiscal year, but no assurances can
be made that the sale/sublease will be successful. Additionally, the Company
entered into a joint-venture with Egyptian investors to open a new laser
cosmetic center in Cairo, Egypt. However, since results of operations were
marginal, the joint venture was terminated. The surgical skin care treatments
performed in the Boston skin care center are administered by board-certified
physicians under contract with the Company's wholly-owned subsidiary, CSCC.
While the target market for the Company's core laser equipment tends to be
medical practice groups and other health care providers, its target market for
its spa and skin care centers are individuals who are typically reached through
entirely different marketing efforts. The cost structures, new client
accretion methods and other demands associated with the Company's spa and skin
care center are largely untested, and the Company could incur significant
losses in relation thereto.
GOVERNMENTAL REGULATION. Medical devices are subject to governmental approval
before they can be utilized for clinical studies or sold commercially. In
addition, the Company's activities in connection with its CSCC business may
subject the Company to additional regulation under state and federal laws. The
process for obtaining the necessary approvals and compliance with applicable
regulations can be costly and time-consuming. Many foreign countries in which
the Company markets or may market its products have similar regulatory bodies
and restrictions. There is no assurance that the Company will be able to
obtain any such government approvals or successfully comply with any such
regulations in a timely and cost-effective manner, if at all, and failure to do
so may have an adverse effect on the Company's financial condition and results
of operations.
RISKS ASSOCIATED WITH PRODUCT LIABILITY. The administration of medical and
cosmetic treatments using laser products is subject to various risks of
physical injury to the patient which may result in product liability or other
claims against the Company. The costs and resources involved in defending or
settling any such claims, or the payment of any award in connection therewith,
may adversely affect the Company's financial condition and operating results.
The Company maintains product liability insurance, but there is no assurance
that its policy will provide sufficient coverage for any claim or claims that
may arise, or that the Company will be able to maintain such insurance coverage
on favorable economic terms.
RAPID TECHNOLOGICAL CHANGE; COMPETITION. The medical laser industry is subject
to rapid and substantial technological development and product innovations. To
be successful, the Company must be responsive to new developments in laser
technology and new applications of existing technology, and the Company's
financial
20
condition and operating results may be adversely affected by the failure of new
or existing products to compete favorably in response to such technological
developments. In addition, the Company competes against numerous other
companies offering products similar to those of the Company and/or alternative
products and technologies, some of which have greater financial, marketing and
technical resources than the Company. There can be no assurance the Company
will be able to compete successfully these companies. In addition, the
Company's CSCC operations face a wide range of competitors including hair
salons, health spas, massage therapists, aestheticians, health and fitness
clubs, personal trainers, dermatologists, plastic surgeons, cosmetic laser
centers and cosmetic retailers. The Company also believes its CSCC operations
will face competition from laser manufacturing companies that have, or may
develop, plans to open facilities based on concepts similar to the Candela
LaserSpa(TM) concept. Such competition could have a material adverse effect on
the Company's business, financial condition and results of operations.
RELIANCE ON ATTRACTING AND RETAINING KEY EMPLOYEES. The Company's success will
depend in large part on its ability to attract and retain highly-qualified
scientific, technical, managerial, sales and marketing, management and other
personnel. Competition for such personnel is intense and any decline in the
Company's ability to attract and retain such personnel may have adverse effects
on its financial condition and operating results.
Item 7a. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
- ------- ----------------------------------------------------------
At June 27, 1998 the Company held foreign currency forward contracts with
notional value totaling approximately $1,386,000 (183,687,568 Japanese Yen)
compared to $500,000 (58,625,000 Japanese Yen) at June 28, 1997. These
contracts have maturities prior to October 19, 1998. The carrying and net fair
value of these contracts at June 27, 1998 was $0 and $127,000, respectively,
compared to $0 and $12,000, respectively, at June 28, 1997.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
- ------ -------------------------------------------
Financial statements and supplementary data are included herein and are indexed
under item 14 (a) (1)-(2).
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
- ------ ---------------------------------------------------------------
FINANCIAL DISCLOSURE
--------------------
None.
21
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
- ------- --------------------------------------------------
For information with respect to the Directors of the Company, see the section
entitled "Election of Directors" appearing in the Company's Proxy Statement in
connection with its 1998 Annual Meeting of Shareholders, which section is
incorporated herein by reference. The current executive officers of the
Company are set forth under the caption "Executive Officers" in Item 1 of this
Form 10-K.
Item 11. EXECUTIVE COMPENSATION
- ------- ----------------------
See the section entitled "Executive Compensation and Other Information
Concerning Officers and Directors" appearing in the Company's Proxy Statement
in connection with its 1998 Annual Meeting of Shareholders, which section is
incorporated herein by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
- ------- --------------------------------------------------------------
See the section entitled "Security Ownership of Certain Beneficial Owners and
Management" appearing in the Company's Proxy Statement in connection with its
1998 Annual Meeting of Shareholders, which section is incorporated herein by
reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
- ------- ----------------------------------------------
See the section entitled "Certain Transactions" appearing in the Company's
Proxy Statement in connection with its 1998 Annual Meeting of Shareholders,
which section is incorporated herein by reference.
22
PART IV
-------
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
- ------- ---------------------------------------------------------------
(a) The following items are filed as part of this report:
(1) Consolidated Financial Statements:
---------------------------------
Report of Independent Accountants F-1
Consolidated Balance Sheets - June 27, 1998 and June 28, 1997 F-2
Consolidated Statements of Operations - Years ended June 27,1998,
June 28, 1997 and June 29, 1996 F-3
Consolidated Statements of Stockholders' Equity - Years Ended
June 27, 1998, June 28, 1997 and June 29, 1996 F-4
Consolidated Statements of Cash Flows - Years Ended June 27, 1998,
June 28, 1997 and June 29, 1996 F-5
Notes to Consolidated Financial Statements F-6
(2) Consolidated Financial Statement Schedules:
------------------------------------------
Schedule II - Valuation and Qualifying Accounts F-20
The report of the registrant's independent accountants with respect to the
above-listed financial statements and financial statement schedule appears on
page F-1 of this report.
All other financial statements and schedules not listed have been omitted since
the required information is included in the consolidated financial statements
or the notes thereto, or is not applicable, material or required.
(3) Exhibits: Except as otherwise noted, the following documents are
--------
incorporated by reference from the Company's Registration Statement on Form
S-3 (File Number 33-24565):
3.1 Certificate of Incorporation, as amended
3.2 <FN9> By-laws of the Company, as amended and restated
3.3 <FN1> Agreement of Merger between Candela Corporation, Inc., a Massachusetts corporation, and Candela Laser Corporation, a
Delaware corporation
4.1 <FN6> Form of Rights Agreement dated as of September 4, 1992 between the Company and The First
National Bank of Boston, as Rights Agent, which includes as Exhibit A thereto the Form of
Rights Certificate
10.1 <FN1> 1985 Incentive Stock Option Plan
10.2 1987 Stock Option Plan
10.2.1 <FN2> 1989 Stock Plan
10.2.2 <FN3> 1990 Employee Stock Purchase Plan
10.2.3 <FN3> 1990 Non-Employee Director Stock Option Plan
10.2.4 <FN7> 1993 Non-Employee Director Stock Option Plan
10.3 <FN7> Lease for premises at 526 Boston Post Road, Wayland, Massachusetts
10.4 <FN7> Lease for premises at 530 Boston Post Road, Wayland, Massachusetts
10.5 Patent License Agreement between the Company and Patlex Corporation effective as of July 1, 1988
10.6 <FN4> License Agreement among the Company, Technomed International, Inc. and Technomed
International S.A. dated as of December 20, 1990
10.7 <FN5> License Agreement between the Company and Pillco Limited Partnership effective as of October 1,
1991
10.8 <FN8> Distribution Agreement between the Company and Cryogenic Technology Limited, dated October 15, 1993
23
<FN10> Asset Purchase Agreement between the Company and Derma-Laser,
Limited and Derma-Lase, Inc. dated June 23, 1994.
Subsidiaries of the Company
Consent of PricewaterhouseCoopers LLP (Independent Accountants)
Financial Data Schedule 27
<FN1> Previously filed as an exhibit to Registration Statement No.
33-54448B and incorporated herein by reference.
<FN2> Previously filed as an exhibit to the Company's Amended and
Restated Annual Report on Form 10-K for the fiscal year ended
June 30, 1988, and incorporated herein by reference.
<FN3> Previously filed as an exhibit to the Company's Annual Report on
Form 10-K for the fiscal year ended June 30, 1990, and
incorporated herein by reference.
<FN4> Previously filed as an exhibit to Form 10-Q for the quarter
ended December 29, 1990, and incorporated herein by reference.
<FN5> Previously filed as an exhibit to Form 10-Q for the quarter
ended September 28, 1991, and incorporated herein by reference.
<FN6> Previously filed as an exhibit to Form 8-K, dated September 8,
1992, and incorporated herein by reference.
<FN7> Previously filed as an exhibit to the Company's Annual Report
on Form 10-K for the fiscal year ended July 3, 1993, and
incorporated herein by reference.
<FN8> Previously filed as an exhibit to Form 10-Q for the quarter
ended January 1, 1994, and incorporated herein by reference.
<FN9> Previously filed as an exhibit to Form 10-Q for the quarter
ended April 2, 1994, and incorporated herein by reference.
<FN10> Previously filed as an exhibit to the Company's Annual Report
on Form 10-K for the fiscal year ended July 2, 1994, and
incorporated herein by reference.
(b) Reports on Form 8-K. No reports on Form 8-K were filed by the
Company during the fourth quarter of the fiscal year ended June 27,
1998.
(c) The Company hereby files, as part of this Form 10-K, the exhibits
listed in Item 14(a)(3) above.
24
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized, on September 22, 1998.
CANDELA CORPORATION
By: Gerard E. Puorro
-----------------
Gerard E. Puorro, President,
Chief Executive Officer and Director
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
Signature Title Date
- ------------------- ------------- ---------
Gerard E. Puorro President, Chief Executive September 25, 1998
- -------------------- Officer, and Director
Gerard E. Puorro (Principal Executive Officer)
F. Paul Broyer Senior Vice President of September 25, 1998
- -------------------- Finance and Administration,
F. Paul Broyer Treasurer and Chief Financial
Officer
Kenneth D. Roberts Chairman of the Board September 25, 1998
- -------------------- of Directors
Kenneth D. Roberts
Richard J. Cleveland Director September 25, 1998
- ---------------------
Richard J. Cleveland
Robert E. Dornbush Director September 25, 1998
- ---------------------
Robert E. Dornbush
Theodore G. Johnson Director September 25, 1998
- ---------------------
Theodore G. Johnson
Douglas W. Scott Director September 25, 1998
- ---------------------
Douglas W. Scott
25
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and Stockholders of Candela Corporation:
In our opinion, the consolidated financial statements listed in the index
appearing under Item 14(a)(1) on page 23 present fairly, in all material
respects, the financial position of Candela Corporation and its Subsidiaries at
June 27, 1998 and June 28, 1997, and the results of their operations and their
cash flows for each of the three years in the period ended June 27, 1998, in
conformity with generally accepted accounting principles. In addition, in our
opinion, the financial statement schedules listed in the index appearing under
Item 14(a)(2) on page 23 present fairly, in all material respects, the
information set forth therein when read in conjunction with the related
consolidated financial statements. These financial statements and financial
statement schedules are the responsibility of the Company's management; our
responsibility is to express an opinion on these financial statements based on
our audits. We conducted our audits of these statements in accordance with
generally accepted auditing standards which require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. An audit includes examining, on a test
basis, evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and significant estimates
made by management, and evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for the
opinion expressed above.
Boston, Massachusetts PricewaterhouseCoopers LLP
July 29, 1998, except for the information
in the first paragraph of note 6, for
which the date is August 7, 1998
F-1
Candela Corporation and Subsidiaries
Consolidated Balance Sheets
June 27, 1998 and June 28, 1997
(dollars in thousands)
Assets 1998 1997
- ------ --------- --------
Current assets:
Cash and cash equivalents (Note 1) $ 1,615 $ 2,674
Accounts receivable (net of allowance of $1,038 and
$197 in 1998 and 1997, respectively)(Notes 1 & 6) 8,419 8,848
Notes receivable 1,486 1,284
Inventories (Notes 1 & 3) 7,241 6,776
Other current assets 200 522
-------- -------
Total current assets 18,961 20,104
Property and equipment, net (Note 4) 3,120 3,523
Other assets 523 1,210
-------- -------
Total assets $ 22,604 $24,837
======== =======
Liabilities and Stockholders' Equity
- ------------------------------------
Current liabilities:
Accounts payable $ 4,292 $ 5,879
Accrued payroll and related expenses 1,319 833
Accrued warranty costs 2,012 1,338
Income taxes payable 335 516
Restructuring reserve (Note 12) 1,995 0
Other accrued liabilities 957 608
Lines of credit and short-term notes(Note 6) 3,052 1,000
Current portion of long-term debt (Note 6) 597 827
Deferred income (Note 5) 1,763 2,071
-------- -------
Total current liabilities 16,322 13,072
Long-term debt (Note 6) 887 1,519
Commitments and contingencies(Note 6) -- --
Stockholders' equity (Note 8):
Common stock, $.01 par value: 30,000,000
shares authorized; 5,479,020 and
5,419,913 shares issued and outstanding
in 1998 and 1997, respectively 55 54
Additional paid-in capital 17,407 17,223
Accumulated deficit (11,337) (6,885)
Cumulative translation adjustment (730) (146)
-------- -------
Total stockholders' equity 5,395 10,246
-------- -------
Total liabilities and stockholders' equity $ 22,604 $24,837
======== =======
The accompanying notes are an integral part of the consolidated financial
statements.
F-2
Candela Corporation and Subsidiaries
Consolidated Statements of Operations
For the years ended June 27, 1998, June 28, 1997, and June 29, 1996
(in thousands, except per share data)
1998 1997 1996
-------- -------- --------
Revenue:
Product sales $25,917 $25,601 $20,403
Services and other revenue 11,108 9,904 10,010
------- ------- -------
Total revenue 37,025 35,505 30,413
Cost of sales:
Product sales 11,272 11,195 9,159
Services and other revenue 9,435 7,455 7,674
------- ------- -------
Total cost of sales 20,707 18,650 16,833
------- ------- -------
Gross profit 16,318 16,855 13,580
Operating expenses:
Research and development 2,399 2,488 1,818
Selling, general and administrative 15,271 13,680 9,873
Restructuring charge 2,609 0 0
------- ------- -------
Total operating expenses 20,279 16,168 11,691
------- ------- -------
Income (loss) from operations (3,961) 687 1,889
Other income (expense)
Interest income 42 84 93
Interest expense (235) (107) (49)
Other expense (123) (26) (207)
------- ------- -------
Total other expense (316) (49) (163)
------- ------- -------
Income (loss) before income taxes (4,277) 638 1,726
Provision for income taxes 175 400 481
------- ------- -------
Net income (loss) $(4,452) $ 238 $ 1,245
======= ======= =======
Basic earnings (loss) per share $ (0.81) $ 0.04 $ 0.23
Diluted earnings (loss) per share $ (0.81) $ 0.04 $ 0.22
======= ======= =======
Weighted average shares outstanding 5,479 5,398 5,321
Adjusted weighted average shares
outstanding 5,479 5,673 5,652
======= ======= =======
The accompanying notes are an integral part of the consolidated financial
statements.
F-3
Candela Corporation and Subsidiaries
Consolidated Statements of Stockholders' Equity
For the years ended June 27, 1998, June 28, 1997, and June 29, 1996
(in thousands)
Additional Cumulative
Paid-in Accumulated Treasury Translation
Common Stock Capital (Deficit) Stock Adjustment
------------------ ---------- ----------- -------------- -----------
Shares Amount Shares Amount Total
------ ------ ------ ------ -----
- ------------------------------------------------------------------------------------------------------------------------
Balance, July 1, 1995 5,496 $54 $18,349 $ (8,294) (197) $(1,574) $ 551 $ 9,086
Sale of common stock
under stock plans 86 1 244 245
Dividend paid by Le Pli (26) (26)
Net income 1,245 1,245
Retirement of Treasury
Stock (197) (2) (1,572) 197 1,574 0
Conversion of
Spa Management,Inc.
to a C-Corporation 48 (48) 0
Currency translation
adjustment (585) (585)
- ------------------------------------------------------------------------------------------------------------------------
Balance June 29, 1996 5,385 53 17,069 (7,123) 0 0 (34) 9,965
Sale of common stock
under stock plans 35 1 154 155
Net income 238 238
Currency translation
adjustment (112) (112)
- ------------------------------------------------------------------------------------------------------------------------
Balance June 28, 1997 5,420 54 17,223 (6,885) 0 0 (146) 10,246
Sale of common stock
under stock plans 59 1 184 185
Net loss (4,452) (4,452)
Currency translation
adjustment (584) (584)
- ------------------------------------------------------------------------------------------------------------------------
Balance June 27, 1998 5,479 $55 $17,407 $(11,337) 0 $ 0 $(730) $ 5,395
- ------------------------------------------------------------------------------------------------------------------------
The accompanying notes are an integral part of the consolidated financial
statements.
F-4
Candela Corporation and Subsidiaries
Consolidated Statements of Cash Flows
For the years ended June 27, 1998, June 28, 1997, and June 29, 1996
(In thousands)
1998 1997 1996
-------- -------- --------
Cash flows from operating activities:
Net income (loss) $(4,452) $ 238 $ 1,245
Adjustments to reconcile net income (loss)
to net cash provided by (used for)
operating activities:
Depreciation and amortization 815 666 475
Provision for bad debts 844 36 36
Provision for restructuring charges 2,609 - -
Gain on disposal of equipment - - (8)
Increase(decrease) in cash from working capital:
Accounts receivable (950) (2,628) (1,945)
Notes receivable (434) 620 (545)
Inventories (810) (1,216) (590)
Other current assets 314 (188) 74
Other assets 664 (529) (171)
Accounts payable (1,046) 2,945 1,552
Accrued payroll and related expenses 491 88 130
Deferred income (241) 145 315
Accrued warranty costs 683 445 278
Income taxes payable (154) 181 (222)
Restructuring reserve (501) 0 0
Other accrued liabilities 303 (395) 90
------- ------- -------
Net cash provided by (used for) operating
activities (1,865) 408 714
Cash flows from investing activities:
Proceeds from sale of assets 24 50 10
Purchases of property and equipment (401) (1,867) (377)
------- ------- -------
Net cash used for investing activities (377) (1,817) (367)
Cash flows from financing activities:
Net borrowings from lines of credit 1,700 1,000 -
Proceeds from issuance of debt 480 655 479
Principal payments on debt (441) (422) (225)
Payments of capital lease obligations (390) (258) (125)
Proceeds from issuance of common stock 184 155 294
Payment of dividends - - (26)
------- ------- -------
Net cash provided by financing activities 1,533 1,130 397
Effect of exchange rate changes on
cash and cash equivalents (350) (88) (268)
------- ------- -------
Net increase (decrease) in cash and
cash equivalents (1,059) (367) 476
Cash and cash equivalents at beginning
of period 2,674 3,041 2,565
------- ------- -------
Cash and cash equivalents at end of period $ 1,615 $ 2,674 $ 3,041
======= ======= =======
Cash paid during the year for:
Interest $ 235 $ 107 $ 50
Income taxes $ 356 $ 492 $ 807
The accompanying notes are an integral part of the consolidated financial
statements.
F-5
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Summary of Significant Accounting Policies
Basis of Presentation
The consolidated financial statements include the accounts of Candela
Corporation and its wholly-owned subsidiaries. All intercompany accounts and
transactions have been eliminated. In August 1995, the Company incorporated a
wholly-owned subsidiary, Candela Skin Care Centers, Inc. (CSCC). In June 1996,
the Company acquired all of the outstanding capital stock of Spa Management,
Inc. which was accounted for using the pooling of interests method of
accounting. (See Note 2)
The Company's fiscal year ends on the Saturday nearest June 30.
Use of Estimates
The presentation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period. It
is the belief of the Company's management that all necessary adjustments have
been made for a proper presentation of results. Actual results could differ
from those estimates and impact future results of operations and cash flows.
Cash and Cash Equivalents
The Company classifies investments purchased with a maturity at the date of
acquisition of three months or less as cash equivalents. These are valued at
cash plus accrued interest which approximates market value. At June 27, 1998
and June 28, 1997, substantially all cash equivalents were invested in
overnight Repurchase Agreements or U.S. Treasury Bills with a major bank.
Financial Instruments
The Company operates internationally, with sales offices, customers, and
vendors in several countries outside of the United States. The Company may
reduce its exposure to fluctuations in foreign exchange rates by creating
offsetting positions through the use of foreign currency forward contracts, a
type of derivative financial instrument. Foreign currency exposures are
accounted for on an accrual basis. The Company does not use derivative
financial instruments for trading or speculative purposes, nor is the Company a
party to leveraged derivatives.
At June 27, 1998 the Company held foreign currency forward contracts with
notional value totaling approximately $1,386,000 (183,687,568 Japanese Yen)
compared to $500,000 (58,625,000 Japanese Yen) at June 28, 1997. These
contracts have maturities prior to October 19, 1998. The carrying and net fair
value of these contracts at June 27, 1998 was $0 and $127,000, respectively,
compared to $0 and $12,000, respectively, at June 28, 1997.
F-6
Accounts Receivable and Notes Receivable
The Company's trade accounts receivables and notes receivables are primarily
from sales to end users and distributors servicing the dermatology and urology
markets, and reflect a broad domestic and international customer base. The
Company does not require collateral and has not historically experienced
significant credit losses related to receivables from individual customers or
groups of customers in any particular industry or geographic area.
Inventory
Inventory is stated at the lower of cost (first-in, first-out method) or
market, using a standard costing system.
Property and Equipment
Purchased property and equipment is recorded at cost. Property and equipment
purchased under capital lease arrangements is recorded at the lesser of cost or
the present value of the minimum lease payments required during the lease
period. Laser systems used for testing are capitalized at cost. Significant
improvements are capitalized; maintenance and repairs are charged to expense as
incurred. Upon sale or retirement of property and equipment, the costs and
accumulated depreciation are removed from the accounts and any resulting gain
or loss is included in income from operations. Depreciation and amortization
are provided using the straight-line method over estimated useful lives as
follows:
Number of Years
---------------
Leasehold improvements and assets under capital lease 2 to 5
Office furniture and other equipment 3 to 5
Laser systems 3
Revenue Recognition
Product sales - Revenue from product sales, except sales to certain
distributors, are recognized at the time of shipment. Shipments made to
distributors, for which payment to the Company is dependent on resale of the
system, are not recognized as revenue unless the distributor demonstrates that
the system is sold.
Grants - Revenue from U.S. government contracts granted under the Small
Business Innovation Research program. Government contracts limit reimbursement
to 100% of allowable direct costs and a negotiated rate for indirect costs.
The revenue is recognized as reimbursable costs are incurred.
Service - Revenue from the sale of service contracts is deferred and recognized
on a straight-line basis over the contract period. Revenue from service
administered through CSCC is recognized as the services are provided. Amounts
received from the sale of gift certificates by CSCC are deferred and recognized
as revenue when the services are provided.
Research and Development
Research and development costs are expensed as incurred.
F-7
Foreign Currency Translation
The financial statements of the Company's foreign subsidiaries are translated
into U.S. dollars in accordance with Statement of Financial Accounting
Standards (SFAS) No. 52, "Foreign Currency Translation." Assets and
liabilities are translated into U.S. dollars at current exchange rates, while
income and expense items are translated at average rates of exchange prevailing
during the year. Exchange gains and losses arising from translation of the
Japanese and Spanish subsidiary balance sheets are accumulated as a separate
component of stockholders' equity. Net exchange losses resulting from foreign
currency transactions amounted to $138,000, $60,000 and $420,000 for fiscal
1998, 1997 and 1996, respectively, and are included in other expense.
Product Warranty Costs
The length of the Company's warranty on end user sales of medical devices is
generally one year on parts and labor. Distributor sales generally include a
parts warranty only. Estimated future costs for initial product warranties are
provided for at the time of sale.
Earnings (Loss) Per Share
In February 1997, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards ("SFAS") No. 128 "Earnings per
Share" ("SFAS 128"). SFAS 128 replaced the calculation of primary and fully
diluted earnings per share with basic and diluted earnings per share. Unlike
primary earnings per share, basic earnings per share exclude any dilutive
effects of options, warrants and convertible securities. Diluted earnings per
share is similar to the previously reported fully diluted earnings per share.
All earnings (loss) per share amounts have been restated to conform with SFAS
128 requirements.
(numbers in thousands except per share amounts)
For the years ended
-------------------------------------------
June 27, June 28, June 29,
1998 1997 1996
------------- ----------- ----------
NUMERATOR
- ----------
Net income(loss) $(4,452) $ 238 $1,245
======= ====== ======
DENOMINATOR
- ------------
BASIC EARNINGS PER SHARE
- -------------------------
Weighted average shares
outstanding 5,479 5,398 5,321
------- ------ ------
Earnings(loss) per share $ (0.81) $ 0.04 $ 0.23
======= ====== ======
DILUTED EARNINGS PER SHARE
- ---------------------------
Weighted average shares
outstanding 5,479 5,398 5,321
Effect of dilutive options 0 275 331
------- ------ ------
Adjusted weighted average
shares outstanding 5,479 5,673 5,652
------- ------ ------
Earnings(loss) per share $ (0.81) $ 0.04 $ 0.22
======= ====== ======
Dilutive options under FAS 128 9
=======
F-8
Accounting for Stock-Based Compensation
The company has elected the disclosure-only alternative permitted under SFAS
123, "Accounting for Stock-Based Compensation" ("SFAS 123"). The Company has
disclosed herein pro forma net income and pro forma earnings per share in the
footnotes using the fair value based method for fiscal 1998, 1997, and 1996.
New Accounting Pronouncements
In June 1997, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standard No. 130 Reporting Comprehensive Income ("SFAS
130") which establishes standards for reporting and display of comprehensive
income and its components (revenue, expenses, gains and losses) in a full set
of general purpose financial statements. Management has not yet evaluated the
effects of this change on its reporting of income. The Company will adopt SFAS
130 for its fiscal year ending July 3, 1999.
In June 1997, the FASB issued Statement of Financial Accounting Standard No.
131 ("SFAS 131"), "Disclosure about Segments of an Enterprise and Related
Information." Based on the management approach to segment reporting, SFAS No.
131 establishes requirements to report selected segment information quarterly
and to report entity-wide disclosures about products and services, major
customers and the countries in which the entity holds material assets and
reports material revenue. The Company has adopted SFAS No. 131 for its fiscal
year ending July 3, 1999, and management is currently evaluating its effects on
the Company's reporting of segment information.
2. Pooling of Interests
On June 27, 1996, the Company acquired all of the outstanding shares of capital
stock of Spa Management, Inc. The acquisition was effected through an exchange
of 60,317 shares of the Company's common stock for all of the outstanding
shares of capital stock of Spa Management, Inc. This transaction has been
accounted for using the pooling of interests method of accounting. Spa
Management, Inc., d/b/a Le Pli at the Heritage(Le Pli) was formed in May 1994,
and is a Boston-based health spa with approximately 60 employees at the time of
acquisition and specializes in personal care and health and beauty services.
Le Pli (currently operating as Candela Skin Care Center of Boston, Inc.)
operates as a wholly-owned subsidiary of CSCC.
The following information presents certain income statement data of Candela
Corporation and Spa Management, Inc. for the periods prior to the acquisition.
The acquisition was substantially coincident with the fiscal year end close.
(in thousands)
Candela Spa
Corporation Management, Inc. Total
----------- ---------------- -------
Revenue for:
Year ending
June 29, 1996 $28,434 $1,979 $30,413
Net Income (Loss) for:
Year ending
June 29, 1996 $ 1,210 $ 35 $ 1,245
F-9
The accompanying consolidated financial statements of the Company have been
prepared to give retroactive effect to the acquisition of Le Pli. All prior
period historical consolidated financial statements presented herein have been
restated to include the financial position, results of operations, and cash
flows of Le Pli.
3. Inventories
Inventories consist of the following at June 27, 1998 and June 28, 1997 (in
thousands):
1998 1997
------ ------
Raw Materials $3,110 $2,429
Work in process 1,062 1,023
Finished goods 3,069 3,324
------ ------
$7,241 $6,776
====== ======
4. Property and Equipment
Property and equipment consists of the following at June 27, 1998 and
June 28, 1997 (in thousands):
1998 1997
------ ------
Leasehold improvements $2,033 $2,014
Office furniture 819 1,064
Laser systems 483 483
Computers and other equipment 4,544 4,271
------ ------
7,879 7,832
Less accumulated depreciation and amortization 4,759 4,309
------ ------
Property and equipment, net $3,120 $3,523
====== ======
Depreciation expense was approximately $684,000, $616,000, and $552,000 for
fiscal 1998, 1997 and 1996, respectively.
Assets under capital lease obligations of $1,648,000 and $1,747,000 are
included in property and equipment at June 27, 1998 and June 28, 1997,
respectively. Accumulated depreciation on these assets was $ 818,000 and
$769,000 at June 27, 1998 and June 28, 1997, respectively.
5. Deferred Income
Deferred income consists of the following at June 27, 1998 and June 28, 1997
(in thousands):
1998 1997
------ ------
Service contract revenue $1,026 $1,243
Gift certificate revenue 343 362
Other 394 466
------ ------
$1,763 $2,071
====== ======
F-10
6. Debt and Lease Obligations
Line of Credit
In February 1997, the Company obtained a renewable $3,500,000 revolving credit
agreement with a bank with interest at 1% over the bank's prime lending rate
(9.5%) at June 27, 1998). This line of credit is collateralized by all tangible
and intangible assets plus international accounts receivable covered by credit
insurance, and the pledge of stock of CSCC. The agreement contains restrictive
covenants establishing maximum leverage, certain minimum ratios and minimum
levels of net income. At June 27, 1998 the Company was in violation of one of
the minimum ratio covenants. On August 7, 1998, the lender waived its rights
under the agreement for the violation for the period ended June 30, 1998. As of
June 27, 1998, the Company had utilized $2,700,000 of the line of credit
compared to $1,000,000 as of June 28, 1997. This line of credit expires on
December 1, 1998.
The Company's experience has been to renew its bank financing arrangement
annually, and management believes the Company will be able to renew the above
line of credit on acceptable terms, however there is no assurance that they will
be successful. In addition, the Company continues to evaluate alternative
sources of financing, including both debt and equity arrangements, to ensure the
Company has sufficient liquidity to fund operations throughout the next year.
Should these alternatives not be possible, there could be material adverse
implications for the Company's financial position and operations.
Short-term Debt
In June 1998, the Company obtained a term bank loan denominated in 50,000,000
Japanese Yen($355,467), secured by a customer note receivable, bearing interest
at 1.825% per annum with payment of interest in advance. The amount due at
June 27, 1998, was $352,000, converted at the year-end exchange rate. The
principal became due and was paid in August 1998.
Long-term Debt
The Company's long-term debt consists of the following at June 27, 1998 and
June 28, 1997 (dollars in thousands):
1998 1997
---- ----
Unsecured term bank loan denominated in 60,000,000
Japanese Yen; interest at 1.95% per annum; quarterly
payments of principal and interest through March 1998 $ 0 $ 196
Unsecured term bank loan denominated in 75,000,000
Japanese yen; interest at 1.745% per annum; quarterly
payments of principal and interest through September 1999 294 655
Obligations under capital leases with options to
purchase equipment; interest from 5.8% to 12.31% per annum;
payments of principal and interest through March 2001 1,190 1,495
------ ------
1,484 2,346
Less current portion 597 827
------ ------
Total long-term debt $ 887 $1,519
====== ======
Lease Commitments
The Company leases several facilities and automobiles under noncancellable
lease arrangements. The facility leases may be adjusted for increases in
maintenance and insurance costs above specified levels. In addition, certain
facility leases contain escalation provisions based on certain specified
criteria, and one lease calls for the payment of additional rent based on a
percentage of gross revenues above a base gross sales level for that particular
location. These operating leases expire in various years through 2009. These
leases may be renewed for periods ranging from one to five years.
F-11
Future minimum lease payments under noncancellable operating leases with
initial terms of one year or more consisted of the following at June 27, 1998:
(in thousands)
1999 $ 788
2000 647
2001 645
2002 489
2003 407
Thereafter 894
------
Total minimum lease payments $3,870
======
Total rent expense was approximately $848,000, $772,000 and $607,000 for fiscal
1998, 1997 and 1996, respectively.
The Company had additions to capital lease obligations of approximately
$84,000, $1,240,000, and $400,000 in fiscal 1998, 1997, and 1996 respectively,
for the acquisition of certain equipment. These obligations are collateralized
by the related equipment.
Cash paid for interest, including interest on capital lease obligations,
totaled approximately $235,000, $107,000 and $50,000 for fiscal 1998, 1997, and
1996 respectively.
As of June 27, 1998, the Company's approximate minimum payment requirements
under debt and capital lease obligations are as follows (in thousands):
Fiscal
------
1999 $3,742
2000 516
2001 333
2002 125
------
Total minimum payments 4,716
Less interest 180
------
Present value of minimum payments 4,536
Less current portion 3,649
------
Long-term obligations $ 887
======
8. Stockholders' Equity
Stock Plans
1985, 1987 and 1989 Candela Corporation Stock Option Plans
The 1985, 1987 and 1989 Stock Option Plans (the "Plans") provide for the
granting of incentive stock options to employees for the purchase of common
stock at an exercise price not less than the fair market value of the stock on
the date of grant. The 1987 and 1989 Stock Option Plans also provide for the
granting of non-qualified stock options. The options generally become
exercisable ratably over two or four years from the date of grant and expire
ten years from the date of the grant. The maximum number of shares for
which options may be granted under the 1989 Plan is 1,000,000 shares. The Board
of Directors has terminated the granting of options under the 1985 and 1987
plans. On July 21, 1995, the Board of Directors approved the
F-12
repricing of certain previously outstanding stock options. Options outstanding
at prices ranging from $5.50 to $14.00 were amended to $3.1875, the fair market
value of the stock on that date. In November 1995, the shareholders approved
an increase in the number of shares under the 1989 Plan of 250,000 shares,
changing the maximum number of shares that may be granted to 1,000,000. On
April 28, 1998, the Board of Directors approved the repricing of certain
outstanding stock options priced at $8.75 and $8.125. The exercise price of
these options was amended to $3.25, the fair market value of the stock on that
date.
1996 Candela Skin Care Center Inc. Stock Option Plan
During fiscal year 1996, CSCC adopted the 1996 Incentive and Non-Statutory
Stock Option Plan under which options may be granted enabling the purchase, at
a price not less than the fair market value, of the common stock on the date of
grant for incentive stock options and at a price of not less than the par value
of the common stock for non-qualified stock options. Options granted under
this plan become exercisable at different rates over one to four years from the
date of grant and expire ten years from the date of grant. As of June 27,
1998, there were no options to purchase shares of the subsidiary's common stock
outstanding compared to 188,000 at June 28, 1997. All such options were issued
with an exercise price equal to the fair market value of the subsidiary's
common stock on the date of grant. During fiscal year 1998, the Board of
Directors of Candela Corporation approved the conversion of all outstanding
CSCC stock options to Candela Corporation stock options. CSCC options were
converted at the rate of 0.21053 Candela Corporation options for each CSCC
option. At the time of the conversion there were options for 193,000 shares
outstanding which converted to options for 40,634 Candela Corporation shares at
$4.75 per share, the fair market value of Candela Corporation stock on the date
of the conversion.
1990 and 1993 Candela Corporation Non-Employee Director Stock Option Plans
The 1990 and 1993 Non-Employee Director Stock Option Plans provide for the
issuance of options for the purchase of up to 60,000 and 80,000 shares of
common stock, respectively. Under these plans, each director who is neither an
employee nor an officer receives a one-time grant of an option to purchase
10,000 shares of common stock at an exercise price equal to the fair market
value of the common stock on the date of grant. Under the 1990 and 1993 Plans
options become exercisable in equal amounts over a period of four and two
years, respectively. Shares under these Plans expire four and ten years,
respectively, after the date of grant and are nontransferable.
F-13
The following is a summary of stock option activity under these Plans:
Weighted Average
Number of Exercise Price
Shares Option Price Per Share
--------- -------------- -------------------
Balance at July 1, 1995 752,271 $4.8100
Granted 211,693 $3.1875-$ 9.875 $4.2092
Exercised (72,896) $6.50 -$ 9.625 $3.2015
Canceled (232,965) $2.00 -$15.50 $6.6946
--------
Balance at June 29, 1996 658,103 $4.1300
Granted 296,500 $4.88 -$8.63 $6.9343
Exercised (22,591) $2.00 -$7.25 $3.0484
Canceled (70,755) $2.00 -$9.875 $6.8645
--------
Balance at June 28, 1997 861,257 $4.8800
Granted 243,867 $3.25 -$4.75 $4.1028
Exercised (43,891) $2.75 -$3.375 $3.1202
Canceled (269,973) $2.75 -$9.875 $7.0516
--------
Balance at June 27, 1998 791,260
========
Options available for grant at June 27,1998 163,970
=======
The following table summarizes information about stock options under the Option
Plans outstanding at June 27, 1998:
Options Outstanding Options Exercisable
- ------------------------------------------------- -------------------------------------
Weighted Average Weighted Weighted
Range of Number Remaining Average Number Average
Exercise Outstanding at Contractual Exercise as of Exercise
Prices June 27, 1998 Life (years) Price June 27, 1998 Price
$1.50 -$ 3.1875 237,796 5.01 $ 2.8315 200,296 $2.8561
$3.25 -$ 3.3750 244,330 5.94 $ 3.3249 180,830 $3.3418
$3.4375-$ 5.7500 242,434 8.37 $ 4.9382 68,511 $4.8587
$6.1875-$14.5000 66,700 6.19 $ 7.2007 47,950 $7.083
-------- -------
$1.50 -$14.5000 791,260 6.50 $ 3.9976 497,587 $3.7157
======== =======
The Company applies Accounting Principles Board Opinion No. 25, "Accounting for
Stock Issued to Employees," and related interpretations in accounting for its
option plans. Accordingly, no compensation expense has been recognized for
options granted to employees and directors of the Company. Had compensation
expense for the Company's stock option plans and employee stock purchase plan
been determined based on the fair value at the grant date for awards under
these plans consistent with the methodology prescribed under SFAS No. 123, the
Company's net income and net income per share would have been reduced by
$45,000, or $.01 per share in 1998, $416,000 or $.08 per share in 1997, and
$250,000 or $.04 per share in 1996. The weighted average fair value of the
options granted under the stock option plans and the shares issued under the
employee stock purchase plan for 1998 and 1997, calculated using the Black
Scholes pricing model, was $2.49, $4.93 and $2.77 per share, respectively.
The following assumptions were used in the Black Scholes pricing model for
options granted in 1998, 1997 and 1996, respectively:
F-14
1998 1997 1996
----------- ----------- -----------
risk-free interest rate 5.95% 5.93% 5.93%
estimated volatility 83% 85% 85%
an expected life for stock options six years six years six years
an expected life for stock purchase plan six months six months six months
expected dividends none none none
The effects of applying SFAS No. 123 in this pro-forma disclosure are not
indicative of the pro-forma effect on net income in future years because SFAS
No. 123 does not take into consideration pro-forma expenses related to options
granted prior to 1996.
1990 Candela Corporation Employee Stock Purchase Plan
The 1990 Employee Stock Purchase Plan provides for the sale of up to 500,000
shares of common stock to eligible employees. The shares are issuable at the
lesser of 85% of the average market price on the first or last day of
semiannual periods. Substantially all full-time employees are eligible to
participate in the plan.
The following is a summary of shares issued under this plan:
Range of
Shares Price per share
-------- ---------------
1996 12,594 $1.75 - $4.50
1997 11,483 $5.00
1998 15,216 $2.50 - $3.75
Reserved Shares
The Company has reserved 1,425,186 shares of common stock for issuance under
its stock plans.
Candela Corporation Common Stock Warrants
In connection with a litigation settlement in January 1991, the Company
authorized warrants to purchase 300,000 shares of common stock in March 1992.
The exercise price for the warrants is $6.875 per share, the fair market value
of the Company's common stock on the date of the settlement. These warrants
will expire in November 2000. There were 282,182 warrants issued in December,
1992. During 1997, 199 warrants were exercised. No warrants were exercised
during fiscal 1998, 1996 or 1995. There were 281,983 warrants outstanding at
June 27, 1998.
Candela Corporation Stockholder Rights Plan
On September 4, 1992, the Company adopted a Stockholder Rights Plan under which
it declared a dividend of one common stock purchase Right for each share of the
Company's common stock outstanding on September 22, 1992. The Rights are not
currently exercisable, but would become exercisable if certain triggering
events occur, such as the initiation of certain tender offers for the Company's
common stock. If such an event occurs, each Right would initially entitle
shareholders to purchase one share of the Company's common stock at an exercise
price of $48 per share, subject to adjustment. In the event that the Rights are
exercised after further triggering events, each Right would entitle holders
to purchase, for the exercise price then in effect, shares of the Company's
common stock (or other property, under certain circumstances) having a value of
twice the exercise price.
F-15
Such Rights do not extend to any shareholders whose action triggered the
Rights. The Company can in certain circumstances redeem the Rights at $.005
per Right. The Rights expire on September 22, 2002, unless redeemed earlier by
the Company.
Authorized Shares
The total authorized shares is 30,000,000 as authorized at the 1995 annual
meeting.
Dividends
Dividend distributions made by Le Pli prior to the acquisition, were
principally for reimbursement of income tax liabilities of its former
stockholders due to Le Pli's S-Corporation tax status. The Company currently
intends to retain future earnings for use in its business and, therefore, does
not expect to pay dividends in the foreseeable future.
9. Income Taxes
The components of income before income taxes and the related provision for
income taxes consists of the following for fiscal 1998, 1997 and 1996 (in
thousands):
1998 1997 1996
-------- ------ -----
Income (loss) before income taxes:
Domestic $(4,686) $ (46) $ 698
Foreign 409 684 1,028
------- ----- ------
$(4,277) $ 638 $1,726
======= ===== ======
Provision for income taxes:
Current provision:
Federal $ - $ - $ 75
State 26 19 10
Foreign 149 381 396
------- ----- ------
Total provision for income taxes $ 175 $ 400 $ 481
======= ===== ======
The components of the Company's deferred tax assets consist of the following at
June 27, 1998 and June 28, 1997 (in thousands):
1998 1997
-------- --------
Federal and state net operating loss carryforwards $ 607 $ 660
Federal and state tax credit carryforwards 1,816 1,630
Inventory valuation reserves 787 736
Warranty reserve 771 498
Deferred revenue 352 174
Intercompany profit 265 335
Bad debt reserve 393 59
Restructuring reserve 798 -
Pre-opening expense 349 -
Other 89 21
------- -------
Gross deferred tax asset 6,227 4,113
Valuation allowance (6,227) (4,113)
------- -------
Net deferred tax assets $ 0 $ 0
======= =======
F-16
A reconciliation from the federal statutory tax rate to the effective tax rate
is as follows:
1998 1997 1996
----- ----- -----
Statutory rate 34% 34% 34%
State taxes - 3 1
Differences between foreign and
U.S. tax rates - 21 5
Utilization of deferred tax assets - - (15)
Unbenefitted losses (35) (2) -
Other (3) 7 3
---- ---- ----
Effective tax rate (4)% 63% 28%
==== ==== ====
Income taxes paid were $356,000, $492,000 and $807,000 in fiscal 1998, 1997 and
1996, respectively.
At June 27, 1998, the Company had net operating loss carryforwards available
for federal income tax purposes of approximately $1,786,000 which expire from
2008 to 2012. In addition, the Company has approximately $1,595,000 of credit
carryforwards for federal income tax purposes expiring at various dates through
2012.
10. Segment, Geographic and Major Customer Information
The Company operates principally in two industry segments; the design,
manufacture sale and service of medical devices and related equipment, and the
performance of services in the skin care/health spa industry.
Geographic data
Geographic information for fiscal 1998, 1997 and 1996 is as follows (in
thousands):
1998 1997 1996
--------- -------- --------
Revenue:
United States $24,943 $25,185 $20,886
Intercompany 8,342 6,303 6,043
------- ------- -------
33,285 31,488 26,929
Europe 3,333 818 296
Japan 8,749 9,502 9,231
------- ------- -------
45,367 41,808 36,456
Elimination (8,342) (6,303) (6,043)
------- ------- -------
$37,025 $35,505 $30,413
======= ======= =======
Operating income(loss):
United States $(4,315) $ (12) $ 833
Europe 364 86 (67)
Japan 174 616 1,006
Elimination (184) (3) 117
------- ------- -------
$(3,961) $ 687 $ 1,889
======= ======= =======
Geographic identification
of assets
United States $ 28,911 $27,139 $17,135
Europe 2,575 852 532
Japan 4,372 5,901 5,401
Elimination (13,254) (9,055) (3,734)
-------- ------- -------
$ 22,604 $24,837 $19,334
======== ======= =======
F-17
Line of Business Data
Revenue
Product sales and service $34,322 $33,262 $28,264
Skin care/health spa services 2,703 2,243 2,149
------- ------- -------
Total Revenue $37,025 $35,505 $30,413
======= ======= =======
Operating income (loss)
Product sales and service $ 1,550 $ 4,073 $ 2,583
Skin care/health spa services (5,511) (3,386) (694)
------- ------- -------
Total operating income (loss) $(3,961) $ 687 $ 1,889
======= ======= =======
Depreciation and Amortization
Product sales and service $ 308 $ 281 $ 369
Skin care/health spa services 507 385 106
------- ------- -------
Total Depreciation and Amortization $ 815 $ 666 $ 475
======= ======= =======
Capital Expenditures
Product sales and service $ 241 $ 243 $ 238
Skin care/health spa services 160 1,624 139
------- ------- -------
Total Amortization $ 401 $ 1,867 $ 377
======= ======= =======
United States revenue includes export sales to unaffiliated companies located
principally in Western Europe, the Middle East, and in the Asia-Pacific region,
which approximated $7,695,000, $8,188,000 and $6,245,000 for fiscal 1998, 1997
and 1996, respectively. One distributor customer accounted for 12% and 6% of
total gross receivables at June 27, 1998 and June 28, 1997, respectively.
11. Employee Benefit Plans
The Company offers a savings plan which allows eligible U.S. employees to make
tax-deferred contributions, a portion of which are matched by the Company.
Company contributions vest ratably with three years of employment and amounted
to $58,000, $84,000 and $57,000 in fiscal 1998, 1997 and 1996, respectively.
12. Restructuring Costs and Other Charges
During the second quarter ended December 27, 1997, the Company recorded a
restructuring charge against income in the amount of $2,609,000. This charge
represents the anticipated costs associated with closing the Scottsdale,
Arizona, LaserSpa(TM), including costs of maintaining the facility, write-off
of leasehold improvements, and a reserve against loss upon liquidation of the
equipment at the site. Charges against the reserve for the year ended June 27,
1998 total $614,000, leaving a reserve balance of $1,995,000 at that date. The
Company expects to complete its restructuring during fiscal 1999.
F-18
13. Quarterly Results of Operations (unaudited)
Quarter
1998 First Second Third Fourth
- -------------------------------------------------------------------------
Net Revenues $7,822 $ 8,522 $8,617 $12,063
Gross Profit 3,320 3,698 3,843 5,455
Restructuring charge - 2,609 - -
Net Income (Loss) (851) (4,441) (194) 1,034
Earnings (Loss) per common share
Basic $(0.16) $ (0.82) $(0.04) $ 0.19
Diluted $(0.16) $ (0.82) $(0.04) $ 0.18
Quarter
1997 First Second Third Fourth
- ------------------------------------------------------------------------
Net Revenues $7,639 $ 9,406 $8,790 $ 9,671
Gross Profit 3,754 4,656 4,678 3,768
Net Income (Loss) 510 736 303 (1,310)
Earnings (Loss) per common share
Basic $ 0.09 $ 0.14 $ 0.06 $ (0.24)
Diluted $ 0.09 $ 0.13 $ 0.05 $ (0.24)
F-19
SCHEDULE II
CANDELA CORPORATION
VALUATION AND QUALIFYING ACCOUNTS
For the years ended June 27, 1998, June 28, 1997 and June 29, 1996
COLUMN A COLUMN B COLUMN C COLUMN D COLUMN E
Balance at Additions Deductions Balance at
Beginning Charged to from End of
Description of Period Income Reserves Period
- -----------------------------------------------------------------------------------------------------------------------
Reserves deducted from assets to which they apply (in thousands):
Allowance for doubtful accounts:
Year ended June 27, 1998 $197 $866 $ 25 $1,038
==== ==== ==== ======
Year ended June 28, 1997 $305 $ 42 $150 $ 197
==== ==== ==== ======
Year ended June 29, 1996 $361 $ 36 $ 92 $ 305
==== ==== ==== ======
Restructuring reserve:
Year ended June 27, 1998 $ 0 $2,609 $614 $1,995
==== ====== ==== ======
F-20
EXHIBIT INDEX
Page
----
21 Subsidiaries of the Company 27
23 Consent of PricewaterhouseCoopers LLP,
Independent Accountants 28
27 Financial Data Schedule 29